Dermira Company Profile (NASDAQ:DERM)

About Dermira (NASDAQ:DERM)

Dermira logoDermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DERM
  • CUSIP: N/A
  • Web: www.dermira.com
Capitalization:
  • Market Cap: $974.07 million
  • Outstanding Shares: 41,591,000
Average Prices:
  • 50 Day Moving Avg: $27.10
  • 200 Day Moving Avg: $30.50
  • 52 Week Range: $21.35 - $38.75
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.46
  • P/E Growth: -0.05
Sales & Book Value:
  • Annual Revenue: $24.72 million
  • Price / Sales: 38.58
  • Book Value: $8.95 per share
  • Price / Book: 2.56
Profitability:
  • EBIDTA: ($102,210,000.00)
  • Net Margins: -408.50%
  • Return on Equity: -31.66%
  • Return on Assets: -22.59%
Debt:
  • Debt-to-Equity Ratio: 0.75%
  • Current Ratio: 24.43%
  • Quick Ratio: 24.43%
Misc:
  • Average Volume: 453,020 shs.
  • Beta: 0.8
  • Short Ratio: 16.84
 

Frequently Asked Questions for Dermira (NASDAQ:DERM)

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

How were Dermira's earnings last quarter?

Dermira, Inc. (NASDAQ:DERM) announced its earnings results on Monday, August, 7th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.04. The business had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1 million. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. View Dermira's Earnings History.

Where is Dermira's stock going? Where will Dermira's stock price be in 2017?

9 brokerages have issued twelve-month price targets for Dermira's stock. Their predictions range from $40.00 to $48.00. On average, they expect Dermira's stock price to reach $43.80 in the next year. View Analyst Ratings for Dermira.

What are analysts saying about Dermira stock?

Here are some recent quotes from research analysts about Dermira stock:

  • 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (8/17/2017)
  • 2. Guggenheim analysts commented, "4Q16 results underscore that DERM continues to advance its pipeline of drugs that address large unmet needs in dermatology. Positive clinical data for DRM01 and DRM04 as well as solid execution in 4Q16, give us greater conviction in our positive investment thesis for the stock. We continue to think stock price appreciation will be driven by upward consensus earnings revisions to DERM's pipeline drug sales. We also view DERM as an attractive company in a consolidating industry." (3/2/2017)

Who are some of Dermira's key competitors?

Who are Dermira's key executives?

Dermira's management team includes the folowing people:

  • Thomas G. Wiggans, Chairman of the Board, Chief Executive Officer, Co-Founder
  • Christopher M. Griffith, Senior Vice President - Corporate Development and Strategy, Founder
  • Luis C. Pena, Co-Founder, Chief Development Officer
  • Andrew L. Guggenhime, Chief Financial Officer, Chief Operating Officer
  • Lori Lyons-Williams, Chief Commercial Officer
  • Eugene A. Bauer M.D., Founder, Chief Medical Officer, Director
  • Frederick B. Craves Ph.D., Lead Independent Director
  • Emmanuel Caeymaex, Director
  • David E. Cohen M.D., Independent Director
  • Matthew K. Fust, Independent Director

Who owns Dermira stock?

Dermira's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.45%), NEA Management Company LLC (8.45%), FMR LLC (6.55%), Jennison Associates LLC (6.34%), TimesSquare Capital Management LLC (6.09%) and Vanguard Group Inc. (3.37%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, Eugene A Bauer, Fred B Craves, Luis C Pena, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.

Who sold Dermira stock? Who is selling Dermira stock?

Dermira's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Balyasny Asset Management LLC, Teachers Advisors LLC, TimesSquare Capital Management LLC, Wells Fargo & Company MN, Bank of New York Mellon Corp, TIAA CREF Investment Management LLC and Century Capital Management LLC. Company insiders that have sold Dermira stock in the last year include Andrew Guggenhime, Christopher M Griffith, Eugene A Bauer, Thomas G Wiggans and William R Ringo. View Insider Buying and Selling for Dermira.

Who bought Dermira stock? Who is buying Dermira stock?

Dermira's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Voya Investment Management LLC, Jennison Associates LLC, State Street Corp, Tekla Capital Management LLC, JPMorgan Chase & Co., Vanguard Group Inc. and Nexthera Capital LP. View Insider Buying and Selling for Dermira.

How do I buy Dermira stock?

Shares of Dermira can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dermira's stock price today?

One share of Dermira stock can currently be purchased for approximately $22.93.


MarketBeat Community Rating for Dermira (NASDAQ DERM)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  199
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Dermira (NASDAQ:DERM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $43.80 (91.02% upside)

Analysts' Ratings History for Dermira (NASDAQ:DERM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017Needham & Company LLCReiterated RatingBuy$46.00LowView Rating Details
6/29/2017Evercore ISIInitiated CoverageOutperform$48.00MediumView Rating Details
6/22/2017Cantor FitzgeraldInitiated CoverageOverweight$45.00MediumView Rating Details
5/25/2017MizuhoLower Price TargetBuy -> Buy$42.00 -> $40.00LowView Rating Details
3/16/2017Raymond James Financial, Inc.Initiated CoverageUnderperform -> UnderperformHighView Rating Details
3/15/2017Citigroup Inc.Initiated CoverageUnderperformHighView Rating Details
3/2/2017GuggenheimReiterated RatingBuy -> Positive$40.00N/AView Rating Details
1/3/2017SEB Equity ResearchReiterated RatingReduceN/AView Rating Details
10/5/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
6/2/2016WedbushBoost Price TargetOutperform$42.00 -> $46.00N/AView Rating Details
8/19/2015Cowen and CompanyInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 8/19/2015 forward)

Earnings

Earnings History for Dermira (NASDAQ:DERM)
Earnings by Quarter for Dermira (NASDAQ:DERM)
Earnings History by Quarter for Dermira (NASDAQ DERM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.89)($0.93)$1.00 million$1.07 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.93)($0.21)$22.47 millionViewListenView Earnings Details
11/7/2016Q316($0.72)($0.72)$0.12 millionViewN/AView Earnings Details
8/8/2016Q2($0.86)($0.89)ViewN/AView Earnings Details
5/10/2016Q1($0.94)($0.95)ViewListenView Earnings Details
11/10/2015Q3($0.77)($0.58)$7.30 millionViewN/AView Earnings Details
8/13/2015Q2($0.81)($0.69)ViewN/AView Earnings Details
5/12/2015Q1($0.65)($0.57)ViewN/AView Earnings Details
3/25/2015Q4($0.59)($0.29)$7.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dermira (NASDAQ:DERM)
2017 EPS Consensus Estimate: ($3.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.84)($0.84)($0.84)
Q2 20171($0.81)($0.81)($0.81)
Q3 20171($1.03)($1.03)($1.03)
Q4 20171($1.29)($1.29)($1.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Dermira (NASDAQ:DERM)
Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 83.82%
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/14/2017Fred B CravesDirectorBuy30,000$23.03$690,900.00View SEC Filing  
8/1/2017Thomas G. WiggansCEOSell500$27.58$13,790.00View SEC Filing  
7/5/2017Eugene A BauerInsiderSell2,500$30.00$75,000.00View SEC Filing  
7/3/2017Thomas G. WiggansCEOSell5,000$29.06$145,300.00View SEC Filing  
6/20/2017Eugene A BauerInsiderSell2,500$30.01$75,025.00View SEC Filing  
6/2/2017Thomas G. WiggansCEOSell5,000$27.52$137,600.00View SEC Filing  
5/15/2017Christopher M. GriffithSVPSell1,312$27.07$35,515.84View SEC Filing  
4/17/2017Christopher M. GriffithSVPSell1,303$33.97$44,262.91View SEC Filing  
4/3/2017Eugene A BauerInsiderSell2,500$33.53$83,825.00View SEC Filing  
4/3/2017Thomas G WiggansCEOSell8,000$33.49$267,920.00View SEC Filing  
4/3/2017William R RingoDirectorSell500$34.03$17,015.00View SEC Filing  
3/15/2017Christopher M. GriffithSVPSell1,303$35.79$46,634.37View SEC Filing  
3/1/2017Eugene A BauerInsiderSell2,500$33.61$84,025.00View SEC Filing  
3/1/2017Thomas G WiggansCEOSell11,000$33.54$368,940.00View SEC Filing  
3/1/2017William R RingoDirectorSell500$35.09$17,545.00View SEC Filing  
2/15/2017Christopher M. GriffithSVPSell1,303$30.79$40,119.37View SEC Filing  
2/15/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
2/14/2017Eugene A BauerInsiderSell1,505$30.00$45,150.00View SEC Filing  
2/1/2017Eugene A BauerInsiderSell995$30.00$29,850.00View SEC Filing  
1/17/2017Christopher M. GriffithVPSell1,303$29.11$37,930.33View SEC Filing  
1/4/2017Thomas G WiggansCEOSell8,000$31.06$248,480.00View SEC Filing  
1/4/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
1/3/2017Eugene A BauerInsiderSell2,500$30.07$75,175.00View SEC Filing  
12/16/2016William R RingoDirectorSell125$32.00$4,000.00View SEC Filing  
12/15/2016Christopher M. GriffithVPSell1,303$30.70$40,002.10View SEC Filing  
12/14/2016Eugene A BauerInsiderSell2,500$30.36$75,900.00View SEC Filing  
12/1/2016Thomas G WiggansCEOSell11,000$30.80$338,800.00View SEC Filing  
12/1/2016William R RingoDirectorSell375$32.00$12,000.00View SEC Filing  
11/9/2016Andrew GuggenhimeCFOSell4,100$35.02$143,582.00View SEC Filing  
11/9/2016William R RingoDirectorSell500$32.30$16,150.00View SEC Filing  
11/1/2016Thomas G WiggansCEOSell11,000$31.19$343,090.00View SEC Filing  
10/17/2016Christopher M GriffithVPSell1,303$32.33$42,125.99View SEC Filing  
10/11/2016Andrew GuggenhimeCFOSell10,900$34.34$374,306.00View SEC Filing  
10/3/2016Thomas G WiggansCEOSell11,000$34.60$380,600.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$34.25$17,125.00View SEC Filing  
9/19/2016Andrew GuggenhimeCFOSell15,000$35.01$525,150.00View SEC Filing  
9/15/2016Christopher M GriffithVPSell1,303$33.26$43,337.78View SEC Filing  
9/12/2016Andrew GuggenhimeCFOSell10,000$32.53$325,300.00View SEC Filing  
9/1/2016Thomas G WiggansCEOSell11,000$31.63$347,930.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
8/15/2016Christopher M GriffithVPSell1,303$31.75$41,370.25View SEC Filing  
8/11/2016Andrew GuggenhimeCFOSell10,000$31.02$310,200.00View SEC Filing  
8/1/2016Eugene A BauerInsiderSell2,500$33.18$82,950.00View SEC Filing  
8/1/2016Thomas G WiggansCEOSell11,000$33.19$365,090.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$33.65$16,825.00View SEC Filing  
7/15/2016Christopher M GriffithVPSell1,303$30.02$39,116.06View SEC Filing  
7/11/2016Andrew GuggenhimeCFOSell10,000$30.15$301,500.00View SEC Filing  
7/5/2016Thomas G WiggansCEOSell11,000$29.62$325,820.00View SEC Filing  
7/1/2016Eugene A BauerInsiderSell2,500$29.48$73,700.00View SEC Filing  
6/23/2016Luis C PenaInsiderSell10,000$30.01$300,100.00View SEC Filing  
6/15/2016Luis C PenaInsiderSell10,000$29.47$294,700.00View SEC Filing  
6/13/2016Christopher M GriffithVPSell4,405$30.16$132,854.80View SEC Filing  
6/1/2016Eugene A BauerInsiderSell2,500$31.65$79,125.00View SEC Filing  
6/1/2016Thomas G WiggansCEOSell11,000$31.57$347,270.00View SEC Filing  
5/2/2016Eugene A BauerInsiderSell2,500$25.09$62,725.00View SEC Filing  
5/2/2016Thomas G WiggansCEOSell9,000$25.11$225,990.00View SEC Filing  
4/1/2016Eugene A BauerInsiderSell2,500$20.84$52,100.00View SEC Filing  
4/1/2016Thomas G WiggansCEOSell7,000$20.69$144,830.00View SEC Filing  
3/1/2016Eugene A BauerInsiderSell2,500$22.55$56,375.00View SEC Filing  
3/1/2016Thomas G WiggansCEOSell7,000$22.57$157,990.00View SEC Filing  
2/1/2016Eugene A BauerInsiderSell2,500$27.26$68,150.00View SEC Filing  
2/1/2016Thomas G WiggansCEOSell9,000$27.25$245,250.00View SEC Filing  
1/4/2016Eugene A BauerInsiderSell2,500$33.17$82,925.00View SEC Filing  
1/4/2016Thomas G WiggansCEOSell11,000$33.17$364,870.00View SEC Filing  
12/1/2015Eugene A BauerInsiderSell2,500$29.65$74,125.00View SEC Filing  
11/2/2015Eugene A BauerInsiderSell2,500$27.82$69,550.00View SEC Filing  
10/1/2015Eugene A BauerInsiderSell2,500$22.87$57,175.00View SEC Filing  
9/14/2015Eugene A BauerInsiderSell22,500$28.05$631,125.00View SEC Filing  
11/25/2014Matthew K FustDirectorBuy6,000$16.77$100,620.00View SEC Filing  
10/8/2014Bay City Capital LlcDirectorBuy69,112$16.00$1,105,792.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Dermira (NASDAQ:DERM)
Latest Headlines for Dermira (NASDAQ:DERM)
Source:
DateHeadline
americanbankingnews.com logoDermira, Inc. (DERM) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - August 17 at 9:26 PM
americanbankingnews.com logoDermira, Inc. (DERM) Raised to Sell at BidaskClub
www.americanbankingnews.com - August 16 at 11:32 PM
americanbankingnews.com logoDermira, Inc. (DERM) Director Fred B. Craves Buys 30,000 Shares
www.americanbankingnews.com - August 14 at 10:46 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Dermira Inc.
finance.yahoo.com - August 14 at 6:11 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 6:18 PM
finance.yahoo.com logoIs Dermira Inc (NASDAQ:DERM)'s Confidence In Lebrikizumab Warranted?
finance.yahoo.com - August 11 at 12:07 AM
americanbankingnews.com logoLeerink Swann Comments on Dermira, Inc.'s Q3 2017 Earnings (NASDAQ:DERM)
www.americanbankingnews.com - August 10 at 12:04 PM
streetinsider.com logoDermira (DERM) Enters Pact to License Exclusive, Worldwide Rights to Lebrikizumab
www.streetinsider.com - August 9 at 5:58 PM
News IconBRIEF-Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab
www.businessinsider.com - August 9 at 5:58 PM
americanbankingnews.com logoEquities Analysts Offer Predictions for Dermira, Inc.'s FY2020 Earnings (DERM)
www.americanbankingnews.com - August 9 at 3:02 PM
finance.yahoo.com logoDermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab
finance.yahoo.com - August 8 at 5:32 PM
americanbankingnews.com logoDermira, Inc. (DERM) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 8 at 12:46 PM
nasdaq.com logoDermira Becomes Oversold (DERM)
www.nasdaq.com - August 7 at 6:12 PM
reuters.com logoBRIEF-Dermira Q2 qtrly ‍net loss per share $0.93
www.reuters.com - August 7 at 6:12 PM
finance.yahoo.com logoDermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update 
finance.yahoo.com - August 7 at 6:12 PM
finance.yahoo.com logoDermira reports 2Q loss
finance.yahoo.com - August 7 at 6:12 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) CEO Sells $13,790.00 in Stock
www.americanbankingnews.com - August 2 at 9:38 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - July 28 at 10:27 PM
finance.yahoo.com logoSuffering from excessive perspiration? Don't sweat it, we...
finance.yahoo.com - July 28 at 7:51 PM
benzinga.com logoUCB and Dermira Announce U.S. and EU Regulatory...
www.benzinga.com - July 25 at 5:49 PM
finance.yahoo.com logoUCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
finance.yahoo.com - July 25 at 3:34 AM
finance.yahoo.com logoETFs with exposure to Dermira, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 5:32 PM
finance.yahoo.com logoDermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 21, 2017
finance.yahoo.com - July 21 at 7:35 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Given Buy Rating at Needham & Company LLC
www.americanbankingnews.com - July 18 at 1:18 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 17 at 12:33 PM
finance.yahoo.com logoETFs with exposure to Dermira, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 3:45 PM
finance.yahoo.com logoDermira, Inc. – Value Analysis (NASDAQ:DERM) : July 12, 2017
finance.yahoo.com - July 12 at 6:28 PM
finance.yahoo.com logoDermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 11, 2017
finance.yahoo.com - July 11 at 6:58 PM
americanbankingnews.com logoDermira, Inc. (DERM) Insider Sells $75,000.00 in Stock
www.americanbankingnews.com - July 6 at 8:06 PM
americanbankingnews.com logoInsider Selling: Dermira, Inc. (NASDAQ:DERM) CEO Sells 5,000 Shares of Stock
www.americanbankingnews.com - July 5 at 7:45 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 3 at 3:22 PM
americanbankingnews.com logoEvercore ISI Begins Coverage on Dermira, Inc. (DERM)
www.americanbankingnews.com - June 29 at 6:42 PM
streetinsider.com logoDermira (DERM) Reports Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
www.streetinsider.com - June 26 at 10:37 PM
reuters.com logoBRIEF-Dermira says findings from nonclinical studies evaluating mechanism of action for olumacostat glasaretil in sebum inhibition were published
www.reuters.com - June 26 at 10:37 PM
finance.yahoo.com logoNewly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
finance.yahoo.com - June 26 at 5:34 PM
americanbankingnews.com logoAnalysts Offer Predictions for Dermira, Inc.'s FY2017 Earnings (DERM)
www.americanbankingnews.com - June 26 at 7:41 AM
americanbankingnews.com logoDermira, Inc. (DERM) Now Covered by Cantor Fitzgerald
www.americanbankingnews.com - June 22 at 2:58 PM
finance.yahoo.com logoDermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : June 22, 2017
finance.yahoo.com - June 22 at 10:24 AM
americanbankingnews.com logoEugene A. Bauer Sells 2,500 Shares of Dermira, Inc. (DERM) Stock
www.americanbankingnews.com - June 21 at 8:04 PM
americanbankingnews.com logoDermira, Inc. (DERM) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 20 at 10:30 AM
americanbankingnews.com logoDermira, Inc. (DERM) Raised to Hold at BidaskClub
www.americanbankingnews.com - June 15 at 6:58 PM
americanbankingnews.com logoThomas G. Wiggans Sells 5,000 Shares of Dermira Inc (DERM) Stock
www.americanbankingnews.com - June 5 at 10:19 PM
finance.yahoo.com logoDermira to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 30 at 4:38 PM
americanbankingnews.com logoShort Interest in Dermira Inc (DERM) Grows By 66.8%
www.americanbankingnews.com - May 28 at 7:02 AM
americanbankingnews.com logoDermira Inc (DERM) PT Lowered to $40.00
www.americanbankingnews.com - May 27 at 12:58 AM
americanbankingnews.com logoDermira Inc (DERM) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 26 at 10:50 AM
finance.yahoo.com logoTeva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts
finance.yahoo.com - May 25 at 6:30 PM
americanbankingnews.com logoDermira Inc (DERM) Short Interest Up 2.9% in April
www.americanbankingnews.com - May 22 at 9:16 PM
finance.yahoo.com logoDERMIRA, INC. (DERM)
finance.yahoo.com - May 16 at 9:43 PM
americanbankingnews.com logoInsider Selling: Dermira Inc (DERM) SVP Sells 1,312 Shares of Stock
www.americanbankingnews.com - May 16 at 8:44 PM

Social

Chart

Dermira (DERM) Chart for Saturday, August, 19, 2017

This page was last updated on 8/19/2017 by MarketBeat.com Staff